Search | Clinical Trials Finder

Conditions: Nausea and Vomiting, Nausea, Vomiting
Interventions: Fosaprepitant for Injection, Metoclopramide Injection; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Gastrointestinal Cancer, Nausea Post Chemotherapy
Interventions: fosaprepitant dimeglumine; Drug
Lead sponsor: Philip Philip; Other
Eligibility: 19 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Malignant Digestive System Neoplasm, Nausea and Vomiting
Interventions: Aprepitant, Dexamethasone, Dolasetron Mesylate, Placebo; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Postoperative Nausea and Vomiting
Interventions: Aprepitant plus Ondansetron, Ondansetron plus placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Lymphomas, Solid Tumors, NSCLC, Metastatic Colon Carcinoma, Granulosa Cell Ovarian Cancer
Interventions: TRC102, CT scan, Lomotil, Prochlorperazine, Metoclopramide, 5-HT3 antagonist, Aprepitant, Biopsy; Drug · Diagnostic Test · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Extrahepatic Bile Duct Cancer, Nausea, Vomiting, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions: aprepitant, gemcitabine hydrochloride, capecitabine, fluorouracil, radiation therapy, questionnaire administration, quality-of-life assessment, nausea and vomiting therapy, management of therapy complications; Drug · Procedure · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Cancer
Interventions: aprepitant, dexamethasone, ondansetron, placebo; Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Nausea, Vomiting
Interventions: Ondansetron, Dexamethasone, Aprepitant; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Resected Pancreatic Adenocarcinoma
Interventions: mFOLFIRINOX, Proton beam radiation; Drug · Radiation
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Nausea and Vomiting, Nausea, Vomiting
Interventions: Fosaprepitant 150 mg, Ondansetron 4 mg; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Type 2 Diabetes Mellitus, Hypertension
Interventions: Placebo, Sitagliptin, Aprepitant, Mixed Meal Test (MMT); Drug · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Sezary Syndrome, Pruritus
Interventions: Aprepitant, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Chemotherapy-Induced Nausea and Vomiting
Interventions: Fosaprepitant, Dexamethasone, 5HT3; Drug
Lead sponsor: Lawrence Einhorn; Other
Eligibility: 15 Years and older · Male only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 4
States / cities: Indianapolis, Indiana • St Louis, Missouri • Omaha, Nebraska + 1 more

Conditions: Postoperative Nausea and Vomiting
Interventions: aprepitant 40 mg, ondansetron 4 mg; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 15 Years to 25 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Hematologic Diseases, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia
Interventions: Ondansetron, Aprepitant; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Nausea, Vomiting, Glioma
Interventions: aprepitant, ondansetron; Drug
Lead sponsor: Katy Peters; Other
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cannabis Dependence, Alcohol Dependence, Cannabis Use Disorder, Alcohol Use Disorder
Interventions: aprepitant, Placebo, Manual-guided behavioral counseling; Drug · Behavioral
Lead sponsor: The Scripps Research Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Nausea, Vomiting, Childhood Cancer
Interventions: Ondansetron, dexamethasone, aprepitant, Ondansetron, Dexamethasone, placebo; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 6 Months to 20 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Postoperative Nausea and Vomiting (PONV), Nausea
Interventions: Aprepitant, Ondansetron, Promethazine, Dexamethasone; Drug
Lead sponsor: Sergio Bergese; Other
Eligibility: 18 Years to 85 Years
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nausea and Vomiting, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: Aprepitant, Cyclophosphamide, Dexamethasone, Granisetron hydrochloride; Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Postoperative Nausea
Interventions: Aprepitant, Placebo; Procedure · Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Staten Island, New York

Conditions: Gastroparesis
Interventions: Aprepitant, Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 8
States / cities: San Francisco, California • Stanford, California • Louisville, Kentucky + 5 more

Conditions: Nausea, Vomiting
Interventions: Dexamethasone, Aprepitant, Placebo Dexamethasone; Drug
Lead sponsor: Main Line Health; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Wynnewood, Pennsylvania

Conditions: Nausea and Vomiting, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx
Interventions: fosaprepitant dimeglumine, cisplatin, palonosetron hydrochloride, dexamethasone, Functional Living Index-Emesis Questionnaire, Emesis Diary, Radiotherapy; Drug · Other · Behavioral + 1 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 70 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide

Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy

Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy

Aprepitant for PONV Prophylaxis in Outpatient Plastic Surgery

TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas

Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer

Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant

Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation

Study of Proton Therapy in Adjuvant Pancreatic Cancer

Antiemetic Fosaprepitant To Remedy Nausea and Vomiting

Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure

Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome

Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors

Aprepitant PO vs Ondansetron IV for Prevention of Postoperative Nausea and Vomiting

Ondansetron Versus Aprepitant Plus Ondansetron for Emesis

Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide

Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence

Efficacy of Aprepitant (Emend®) in Children

Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting

Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant

Aprepitant for Post-operative Nausea

Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial

Oral Aprepitant and Lower Dose Dexamethasone Versus Aprepitant Alone for Preventing Postoperative Nausea and Vomiting (PONV) After Elective Laparoscopic Surgeries

Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy